Thus, IL-36 is a valid target for the treatment of plaque psoriasis, since IL-36 signaling is upregulated in plaque psoriasis, and its upregulation is even more pronounced than IL-17A and IL-22, which have already been successfully used as targets for the treatment of psoriasis vulgaris using neutralizing antibodies. This evidence concerns the gene IL17A and psoriasis vulgaris.